BioStock: Alligator’s CEO on current development and the rights issue

Alligator Bioscience got off to a turbocharged 2023 by presenting positive interim results from the phase II OPTIMIZE-1 study with mitazalimab in pancreatic cancer, and the company has continued to deliver positive news during Q1. Now, the company is carrying out a rights issue of approximately 199 MSEK to advance the study even further, among other things. BioStock talked to CEO Søren Bregenholt to discuss the purpose of the rights issue in more depth.

Read the interview with Søren Bregenholt at biostock.se:

https://www.biostock.se/en/2023/05/alligators-ceo-on-current-development-and-the-rights-issue/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/